03.12.2012 • News • AkzoNobel • chemical industry • Management

CEO Ton Büchner Returns to AkzoNobel

The Supervisory Board of AkzoNobel is delighted to announce that CEO Ton Büchner will resume his duties on Friday, December 7, following a full recovery.

"On behalf of the Supervisory Board and the Executive Committee we welcome Ton coming back to the office. It has obviously been a testing time for all of us but now Ton is back as expected, leading the company forward and returning to business as usual," said Karel Vuursteen, Chairman of the Supervisory Board.

AkzoNobel will organize an analyst conference call and media interviews on Friday, December 14. Supervisory Board member Antony Burgmans, and CEO Ton Büchner will answer questions relating to this announcement.

On February 20, 2013, AkzoNobel will announce its Q4 and Full Year 2012 results, and Ton Büchner will give the Strategy Update, postponed from October 22.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Top-Feature

most read